Indication: Medulloblastoma
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
Sub-indication: Medulloblastoma
Drug Study
Principal Investigator: Michael Huang, M.D.Norton Children's Cancer Institute, affiliated with the UofL School of Medicine
Sponsor: Beat Childhood Cancer
